News

NEWS

Company News

Home page

News

Shenzhen Fourth People's Hospital and Realbio Group successfully signed a strategic cooperation agreement

2025-06-23

On October 21, 2024, Shenzhen Fourth People's Hospital (Shenzhen Sami Medical Center) (hereinafter referred to as "the Fourth Hospital"), Shenzhen Realbio Group Co., Ltd. (hereinafter referred to as "Realbio") & Shenzhen Pingshan Entropy Integration Research Institute successfully held a signing ceremony for a strategic cooperation and joint construction laboratory.

View Details

A Successful Conclusion — The 22nd China Association of Clinical Laboratory Practice Expo (CACLP)

2025-03-24

On March 24, 2025, the three-day 22nd China Association of Clinical Laboratory Practice Expo (CACLP) concluded successfully in Hangzhou. Shenzhen Realbio Group (hereinafter referred to as "Realbio"), a leading domestic supplier of raw materials for in-vitro diagnostic reagents, made a striking appearance with a portfolio of flagship products and solutions, joining numerous industry experts, partners, and clients in celebrating this grand event and engaging in forward-looking discussions on the future development of the IVD industry.

View Details

Good News | Realbio Group Listed on Shenzhen's White List of Pilot Enterprises for Special Biomedical Items Subject to Entry-Exit Inspection

2025-01-08

Recently, the Office of the Joint Interdepartmental Regulatory Mechanism for Special Entry-Exit Biomedical Items in Shenzhen published on the website of the Shenzhen Municipal Development and Reform Commission the proposed "White List" of pilot enterprises (institutions) and the Positive List of items for entry-exit special biomedical items for 2024. By virtue of its outstanding heritage in the biomedical field, and after undergoing rigorous material review, expert evaluation, on-site inspection, consultation with relevant departments, and deliberation at the joint interdepartmental meeting, Realbio Group was successfully included in the city's first batch of 13 enterprises and public institutions on the White List. Notably, the core raw materials for its autoimmune disease projects were approved for inclusion on the Positive List of special biomedical items for entry and exit. As a service-platform-oriented enterprise dedicated to IVD core raw materials, Realbio Group has always been committed to driving innovation and development in the industry. The approval and inclusion on the White List this time represents not only an affirmation of the company's past efforts and achievements, but also a powerful boost to its future development. On one hand, it will significantly enhance the company's customs clearance efficiency for special biomedical items and empower its bonded R&D services in biomedical fields, enabling the company to respond to market demands more swiftly and accelerate the translation and application of scientific research outcomes. On the other hand, it will also help elevate the company's competitiveness and influence in the international market, creating more favorable conditions for expanding overseas business and strengthening international cooperation. Looking ahead, Realbio Group will take this as an opportunity to further increase its R&D investment in the biomedical field, strengthen cooperation and exchanges with domestic and international research institutions and enterprises, and contribute its own strength to promoting the high-quality development of the biomedical industry.

View Details

Medica 2024 | REALBIO Invites You to Discover New Opportunities.

2024-11-05

MEDICA 2024 will be held from November 11 to 14 in Düsseldorf, Germany. REALBIO is looking forward to connecting with both current and prospective partners to explore new possibilities. We are confident that our distinctive product portfolio and comprehensive services will address your critical needs. We warmly invite you to visit us at Booth 3H14 – discover our latest innovations, pick up brochures, catalogs, and technical documentation, and share your requirements with us. Our team is ready to provide dedicated support whenever you need it.

View Details

Sekisui Medical and REALBIO Successfully Sign Strategic Cooperation Agreement

2024-07-16

On July 16, 2024, the signing ceremony of the strategic cooperation agreement between Sekisui Medical Technology (China) Co., Ltd. (hereinafter referred to as "Sekisui Medical"), a nationally renowned IVD company, and Shenzhen REALBIO Group Co., Ltd. (hereinafter referred to as "REALBIO") was held as scheduled in Shenzhen. Mr. Takano Tsuyoshi, General Manager of Sekisui Medical, and Mr. Su Shaobo, Chairman of REALBIO, attended the ceremony and signed the agreement on behalf of both parties.

View Details

Good News! Shenzhen REALBIO Group Obtains AEO Advanced Certification Enterprise Certificate.

2024-06-12

Recently, Shenzhen REALBIO Group was awarded the AEO (Authorized Economic Operator) Advanced Certification Enterprise Certificate by China Customs. This marks that REALBIO Group has achieved internationally advanced standards in supply chain management and international trade compliance, and has developed stronger international competitiveness.

View Details

Shenzhen REALBIO Group Successfully Held Randox RIQAS External Quality Assessment Symposium.

2024-06-07

On June 7, 2024, Shenzhen REALBIO Group successfully held the Randox RIQAS External Quality Assessment Symposium at the REALBIO Group headquarters in Pingshan Comprehensive Bonded Zone. The symposium concluded successfully, not only strengthening the cooperation between REALBIO Group and Randox UK, but also providing new opportunities for the Group's product quality improvement and customer service.

View Details

Shenzhen REALBIO Group Conducts In-Depth Exchange in Japan to Expand Cooperation Opportunities in China's IVD Market.

2024-06-07

From May 27 to 30, 2024, a high-level delegation from Shenzhen REALBIO Group visited Japan for a four-day in-depth exchange tour. The main purpose of this visit was to engage with several renowned established Japanese companies, explore the potential for cooperation in the Chinese market, and seek new opportunities for mutual development.

View Details

Sysmex (Wuxi) and Realbio Group have reached a strategic cooperation, jointly developing laboratories, in-vitro diagnostic quality control products, and core raw materials to support the development of the domestic precision medicine industry.

2023-05-04

Sysmex (Wuxi) and Realbio Group reached a strategic cooperation

View Details

< 1 2 3 >

86 755-36560632

+86 13530508971

market@realbiogroup.com

Headquarters address: Building 1, Shenfubao Science and Technology Ecological Industrial Park, No. 18 Jinxiu West Road, Pingshan District, Shenzhen

City Substation

Business License

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

Message

8613026671026

market@realbiogroup.com

+86 0755-4959330

搜索历史清除全部记录

最多显示8条历史搜索记录噢~

All

All
Product Management
News
Introduction
Corporate Outlets
FAQ
Corporate Video
Corporate Brochure